As the global pet obesity rate reaches alarming levels, Okava Pharmaceuticals, a San Francisco-based firm, launched a GLP-1-based pet weight management pilot study, MEOW-1 (Management of Overweight Cats), for obese cats.
The drug, which is an implant of a GLP-1 analogue, mimics the effects of drugs such as Ozempic, Mounjaro, and Wegovy. The implant, a little larger than a microchip, would administer a steady dose of medication, making your pets feel fuller and slowing digestion and hunger - a way to combat obesity. The results from the ongoing study are anticipated in the summer of 2026.
